Accurate dose prediction for clinical trials is essential to ensure patient safety and trial success.
This new whitepaper from the Jackson Laboratory discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models.
In this whitepaper you will learn about:
- The significance of selecting appropriate starting doses in clinical trials.
- Utilising humanised mouse models to mimic human responses.
- Integration of preclinical data and physiological parameters for dose prediction.
- Advantages of refining dosing strategies, minimising risks, and improving trial outcomes.
- Enhancing understanding of drug behaviour, toxicity, and efficacy in humans.
- The potential to revolutionise drug development by optimising dose selection.